Iloperidone for the treatment of schizophrenia

Annals of Pharmacotherapy

Volumn 44, Issue 5, 2010, Pages 863-870

  Marino, Jehan ^a   Caballero, Joshua ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Acute; Iloperidone; Long term; Maintenance studies; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; ILOPERIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGITATION; AKATHISIA; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; STANDING; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; HUMANS; ISOXAZOLES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77951532078     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M603     Document Type: Review

References (20)

1. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002;59:115-123
2. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association, 2000.
3. Bilder RM, Volavka J, Czobor P, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002;52:701-707
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223 (Pubitemid 41345943)
5. Sainati SM, Hubbard JW, Chi E, Grasing K, Brecher MB. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995;35:713-720
6. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317:417-423 (Pubitemid 27014051)
7. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-914 (Pubitemid 34031895)
8. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992;17(suppl):12-16
9. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:553-560 (Pubitemid 34252950)
10. Product information. Fanapt (iloperidone). Rockville, MD: Vanda Pharmaceuticals, Inc., August 2009.
11. Chesson SM, Hsu RS, Dileo EM, Strupczewski JT. HP 873, a potential atypical antipsychotic agent: pharmacokinetics in rats and dogs. Pharmacologist 1991;33:177-182
12. Sedek G, Wolfgang CD. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. Presented at: American Psychiatric Association Annual Meeting, San Diego, CA, May 27, 2007.
13. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(suppl):S4-11. (Pubitemid 351397671)
14. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(suppl):S20-8.
15. Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(suppl): S29-35.
16. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(suppl):S12-9.
17. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;11:1024-1031 Epub 3 June 2008. DOI: 10.1038/mp.2008.52.
18. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009;14:804-819
19. Thompson A, Lavedan C, Volpi S. Absence of weight gain association with the HTRC- 759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatr Res 2010;165:271-273
20. Volpi S, Heaton C, Mack K, et al. Pharmacogenomic analysis shows differences in markers associated with response to low atypical antipsychotics, iloperidone and ziprasidone, in the treatment of patients with schizophrenia. Presented at: 57th Annual Meeting of the American Society of Human Genetics, San Diego, CA, October 23-27, 2007.